Searching across hundreds of databases
Onset of cardiovascular complications as a consequence of atherosclerosis exhibits a circadian incidence with a peak in the morning hours. Although development of atherosclerosis extends for long periods of time through arterial leukocyte recruitment, we hypothesized that discrete diurnal invasion of the arterial wall could sustain atherogenic growth. Here, we show that myeloid cell recruitment to atherosclerotic lesions oscillates with a peak during the transition from the activity to the resting phase. This diurnal phenotype is regulated by rhythmic release of myeloid cell-derived CCL2, and blockade of its signaling abolished oscillatory leukocyte adhesion. In contrast, we show that myeloid cell adhesion to microvascular beds peaks during the early activity phase. Consequently, timed pharmacological CCR2 neutralization during the activity phase caused inhibition of atherosclerosis without disturbing microvascular recruitment. These findings demonstrate that chronic inflammation of large vessels feeds on rhythmic myeloid cell recruitment, and lay the foundation for chrono-pharmacology-based therapy.
Pubmed ID: 29861387 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This unknown targets
View all literature mentionsThis unknown targets Armenian Hamster IgG (H+L)
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis monoclonal targets CD11b
View all literature mentionsThis monoclonal targets Mouse VCAM-1
View all literature mentionsThis monoclonal targets TER-119
View all literature mentionsThis monoclonal targets MAC-2/Gal-3
View all literature mentionsThis monoclonal targets Ly-6G
View all literature mentionsThis monoclonal targets Ly-6C
View all literature mentionsThis monoclonal targets Ly-6G Ly-6C
View all literature mentionsThis monoclonal targets Mouse CXCR2 / IL-8 RB
View all literature mentionsThis polyclonal targets Collagen IV
View all literature mentionsThis monoclonal targets CD62L
View all literature mentionsThis monoclonal targets CD62E (E-Selectin)
View all literature mentionsThis monoclonal targets CD54
View all literature mentionsThis monoclonal targets CD45
View all literature mentionsThis monoclonal targets CD45
View all literature mentionsThis monoclonal targets CD31
View all literature mentionsThis monoclonal targets CD18
View all literature mentionsThis monoclonal targets CD140b
View all literature mentionsThis monoclonal targets CD11a
View all literature mentionsThis monoclonal targets CD115 (c-fms)
View all literature mentionsThis monoclonal targets CD195 (CCR5)
View all literature mentionsThis monoclonal targets Mouse CCR2 Phycoerythrin MAb (Clone 475301)
View all literature mentionsThis monoclonal targets CCL2 (MCP-1)
View all literature mentionsCell line SVEC4-10 is a Transformed cell line with a species of origin Mus musculus
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
